Groundbreaking CRISPR treatment for blindness only works for subset of patients
By Jocelyn Kaiser,
Science
| 11. 17. 2022
After some early but cautious optimism, a company is shelving its pioneering gene-editing treatment for a rare inherited blindness disorder. Editas Medicine announced today the trial trying to use the gene editor CRISPR to treat Leber congenital amaurosis 10 (LCA10) led to “clinically meaningful” vision improvements in only three of 14 patients.
In the study, patients received a subretinal injection of a modified virus carrying genetic material encoding components of CRISPR, a DNA-cleaving enzyme, and two RNA strands to guide the protein to its target sequences. For this trial, CRISPR was designed to snip out a problematic part of a gene called CEP290, which encodes a protein needed by the photoreceptor cells that eyes use to sense light. It was the first trial in the world to directly inject the gene-editing system into the body, rather than applying CRISPR to people’s cells in a lab dish and then reinfusing them.
Two of the patients whose vision improved—a woman treated early in the trial and a 14-year-old boy treated more recently, both of whom received midrange doses—had two defective copies...
Related Articles
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...
By Roni Caryn Rabin, The New York Times | 08.25.2025
Scientists have dreamed for centuries about using animal organs to treat ailing humans. In recent years, those efforts have begun to bear fruit: Researchers have begun transplanting the hearts and kidneys of genetically modified pigs into patients, with varying degrees...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...